Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
cadila healthcare
Jump to
846 Results Found
  • Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher Jan 18, 2021 10:52 PM IST

    Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 3,638.1 crore, according to Prabhudas Lilladher.

  • Cadila Healthcare shares rise 3% on DCGI nod to Phase III clinical trials of COVID-19 vaccine Jan 04, 2021 09:35 AM IST

    Cadila Healthcare shares rise 3% on DCGI nod to Phase III clinical trials of COVID-19 vaccine

    In Phase II, the vaccine ZyCoV-D was found to be safe and elicited a strong immunogenic response.

  • Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial Dec 24, 2020 10:15 PM IST

    Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial

    Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials.

  • Cadila Healthcare shares up 3% on plans to launch COVID-19 vaccine by March 2021 Nov 27, 2020 09:34 AM IST

    Cadila Healthcare shares up 3% on plans to launch COVID-19 vaccine by March 2021

    Zydus Cadila said it will apply for Phase 3 clinical trials of its experimental COVID-19 vaccine in December, and expects to launch it by March 2021.

  • Cadila Healthcare shares up 4% on completion of phase-II trial of COVID vaccine Nov 12, 2020 11:47 AM IST

    Cadila Healthcare shares up 4% on completion of phase-II trial of COVID vaccine

    Based upon the results from its Phase 2 study, Zydus Cadila now plans to conduct a Phase 3 clinical trial in India.

  • Accumulate Cadila Healthcare; target of Rs 497: Dolat Capital Market Nov 07, 2020 06:54 PM IST

    Accumulate Cadila Healthcare; target of Rs 497: Dolat Capital Market

    Dolat Capital Market recommended accumulate rating on Cadila Healthcare with a target price of Rs 497 in its research report dated November 02, 2020.

  • Buy Cadila Healthcare; target of Rs 555: ICICI Direct Nov 07, 2020 01:41 PM IST

    Buy Cadila Healthcare; target of Rs 555: ICICI Direct

    ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 555 in its research report dated November 03, 2020.

  • Sell Cadila Healthcare; target of Rs 357: Prabhudas Lilladher Nov 06, 2020 04:45 PM IST

    Sell Cadila Healthcare; target of Rs 357: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Cadila Healthcare has recommended sell rating on the stock with a target price of Rs 357 in its research report dated November 03, 2020.

  • Buy Cadila Healthcare: target of Rs 530: Sharekhan Nov 05, 2020 05:07 PM IST

    Buy Cadila Healthcare: target of Rs 530: Sharekhan

    Sharekhan is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 530 in its research report dated November 03, 2020.

  • COVID-19 product pipeline and debt reduction add zing to Cadila Healthcare Nov 05, 2020 08:12 AM IST

    COVID-19 product pipeline and debt reduction add zing to Cadila Healthcare

    Cadila Healthcare is working on a potential COVID-19 vaccine and drugs. With key markets, India and the US returning to growth, the success of COVID-19 initiatives can add to the company's revenue momentum

  • Cadila Healthcare shares hit 52-week high as Q2 profit jumps 4-fold Nov 03, 2020 12:04 PM IST

    Cadila Healthcare shares hit 52-week high as Q2 profit jumps 4-fold

    CLSA has maintained buy call on the stock and has raised target to Rs 540 from Rs 525 per share

  • Cadila Health Standalone September 2020 Net Sales at Rs 2,056.90 crore, up 22.24% Y-o-Y Nov 03, 2020 09:22 AM IST

    Cadila Health Standalone September 2020 Net Sales at Rs 2,056.90 crore, up 22.24% Y-o-Y

  • Cadila Health Consolidated September 2020 Net Sales at Rs 3,820.00 crore, up 13.47% Y-o-Y Nov 03, 2020 09:11 AM IST

    Cadila Health Consolidated September 2020 Net Sales at Rs 3,820.00 crore, up 13.47% Y-o-Y

  • Cadila Healthcare Q2 net profit jumps over four-fold to Rs 473.4 crore Nov 02, 2020 07:49 PM IST

    Cadila Healthcare Q2 net profit jumps over four-fold to Rs 473.4 crore

    The company had posted a net profit of Rs 107.2 crore for the corresponding period of the previous financial year, Cadila Healthcare said in a BSE filing.

  • Coronavirus vaccine | Cadila Healthcare planning to boost production capacity Oct 27, 2020 11:54 AM IST

    Coronavirus vaccine | Cadila Healthcare planning to boost production capacity

    The government plans to vaccinate 20-25 crore by July 2021, Union Minister Harsh Vardhan said on October 4.

  • Cadila Healthcare share price rises 2% post USFDA approval Oct 23, 2020 12:00 PM IST

    Cadila Healthcare share price rises 2% post USFDA approval

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

  • Ideas for Profit | What makes Cadila Healthcare a formidable player in COVID times? Sep 25, 2020 03:55 PM IST

    Ideas for Profit | What makes Cadila Healthcare a formidable player in COVID times?

    In this edition of Ideas for Profit, Moneycontrol's Sakshi Batra explains what makes this vaccine candidate a worthy investment bet even after the fading of the HCQS opportunity

  • Cadila: a formidable play in Covid times and beyond Sep 25, 2020 09:39 AM IST

    Cadila: a formidable play in Covid times and beyond

    Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

  • Cadila Healthcare in talks with RDIF to bring COVID-19 vaccine to India; shares hit 52-week high Sep 18, 2020 11:35 AM IST

    Cadila Healthcare in talks with RDIF to bring COVID-19 vaccine to India; shares hit 52-week high

    RDIF has agreed to supply 10 crore doses of the world’s first coronavirus vaccine to Dr Reddy’s Laboratories. However, it wanted to scale up the supply of the vaccine and hence started talks with at least four Indian drug makers, including that of Zydus Cadila.

  • 'Excellent safety' of 2 indigenous COVID-19 candidate vaccines revealed during Phase-I trials: Minister Ashwini Choubey Sep 15, 2020 05:00 PM IST

    'Excellent safety' of 2 indigenous COVID-19 candidate vaccines revealed during Phase-I trials: Minister Ashwini Choubey

    Other companies in India involved in COVID-19 vaccine development are Premas Biotech, Gennova, Mynvax, Epygen Biotech, Luxmatra Innovations, Biological Evans. All candidates are in preclinical development stages, the minister said.

  • Reduce Cadila Healthcare; target of Rs 408: Dolat Capital Aug 17, 2020 05:05 PM IST

    Reduce Cadila Healthcare; target of Rs 408: Dolat Capital

    Dolat Capital recommended reduce rating on Cadila Healthcare with a target price of Rs 408 in its research report dated August 14, 2020.

  • Buy Cadila Healthcare; target of Rs 470: ICICI Direct Aug 10, 2020 01:00 PM IST

    Buy Cadila Healthcare; target of Rs 470: ICICI Direct

    ICICI Direct is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 470 in its research report dated August 06, 2020.

  • Reduce Cadila Healthcare; target of Rs 408: Dolat Capital Aug 09, 2020 09:16 PM IST

    Reduce Cadila Healthcare; target of Rs 408: Dolat Capital

    Dolat Capital recommended accumulate rating on Cadila Healthcare with a target price of Rs 408 in its research report dated August 05, 2020.

  • Hold Cadila Healthcare; target of Rs 402: Emkay Global Financial Aug 08, 2020 02:43 PM IST

    Hold Cadila Healthcare; target of Rs 402: Emkay Global Financial

    Emkay Global Financial recommended hold rating on Cadila Healthcare with a target price of Rs 402 in its research report dated August 05, 2020.

  • Sell Cadila Healthcare; target of Rs 329: Prabhudas Lilladher Aug 08, 2020 12:34 PM IST

    Sell Cadila Healthcare; target of Rs 329: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Cadila Healthcare has recommended sell rating on the stock with a target price of Rs 329 in its research report dated August 06, 2020.

Sections